LUND, Sweden — March 12, 2025 — Cellevate AB, an innovative biotech company developing next-generation cell culture solutions to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as chief technology officer (CTO) and member of the management team.
Dr. Fenge, who has served as a strategic advisor to Cellevate since June 2024, brings more than 30 years of experience in leadership roles within the bioprocessing and biopharmaceutical industries. Previous positions include vice president, R&D Bioprocess at Cytiva, and vice president, Marketing & Product Management at Sartorius, overseeing upstream and downstream development and commercialization. This expertise will be instrumental in scaling up Cellevate’s groundbreaking nanofiber-based cell culture products.
“I am delighted to take on the role of CTO at Cellevate,” Dr. Fenge said. “The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing, and I look forward to supporting the team as we now have moved into commercialization and scale-up.”
“Bringing Dr. Fenge into the management team strengthens our ability to accelerate the commercialization and the strategic partnerships with customers and turnkey solution providers in bioprocessing,” said Laura Chirica, CEO of Cellevate. “Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d® nanofiber cell culture solutions in new therapeutic large-scale applications, develop new product families and position our company as a proven provider in this industry.”
Posted March 14, 2025
Source: Cellevate
